UNSPSC 51292915: Trimipramine

This classification denotes a tricyclic antidepressant with the molecular formula C20H26N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6S082C9NDT, chemically known as 10,11-dihydro-n,n,beta-trimethyl-5h-dibenz(b,f)azepine-5-propanamine but generally known as trimipramine, which bears US NIH Compound Identifier 5584. European Medicines Agency schedules Trimipramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11314MIG.

UNSPSC 51292915 Trimipramine is a Commodity code that nominally describes a single antidepressant drug product, but the recent state and local opportunities tagged to it reflect a much broader pharmaceutical procurement activity: state health agencies and county health systems are soliciting supplies of generic pharmaceuticals, over-the-counter products, naloxone, and drug-deactivation systems through competitive bidding and cooperative purchasing agreements. The work involves supplying finished pharmaceutical products and medical devices to public health entities, with vendors typically required to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) adherence, insurance requirements, and E-Verify employment verification. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple states including Oregon).

Recent opportunities span Florida, Texas, and Minnesota with broader multistate reach through cooperative purchasing. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: deadline date appears inconsistent with post date and is likely a data error in the source). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with no formal award timeline at that stage. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026; this procurement requires vendors to work through three authorized wholesalers and emphasizes price competitiveness (weighted 75 percent in evaluation) alongside cGMP and DSCSA compliance.